Safety Study for NST-001 and the Neuroject Injection Set to Treat Tinnitus
Launched by NEUROSYSTEC CORPORATION · Aug 10, 2009
Trial Information
Current as of May 11, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients able to provide voluntary consent.
- • Severe tinnitus in one ear that began no more than ten years ago.
- • Ear to be treated must be deaf or have profound hearing loss.
- • Subjects with cardiac disease or hypertension, must have stable disease for at least 6 months.
- • Subject must have intact cochlear nerve on the ear to be treated.
- • Women of childbearing potential (i.e., not post-menopausal or surgically sterilized) must agree to use adequate birth control methods as recommended by the study physician.
- Exclusion Criteria:
- • Current diagnosis of bilateral tinnitus.
- • Current diagnosis or history of pancreatitis.
- • Females that are pregnant or lactating.
- • Use of investigational drugs within the previous 30 days.
- • History of drug dependency or other substance abuse.
About Neurosystec Corporation
Neurosystec Corporation is a pioneering biomedical company dedicated to advancing neurotechnology and improving patient outcomes through innovative solutions in neurosurgery and neurorehabilitation. With a focus on developing cutting-edge devices and software, Neurosystec aims to enhance diagnostic accuracy and therapeutic efficacy in the treatment of neurological disorders. Committed to rigorous clinical research and collaboration with healthcare professionals, the company strives to translate scientific discoveries into practical applications that empower patients and improve quality of life. Through its dedication to excellence and innovation, Neurosystec Corporation is at the forefront of transforming the landscape of neurosurgical care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Mont Godinne, , Belgium
Bobigny, Cedex, France
Patients applied
Trial Officials
Bruno Frachet, MD
Principal Investigator
Hôpital Avicenne
Pierre Garin, MD
Study Director
Cliniques Universitaries U.C.L.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials